期刊文献+

贝达喹啉、氯法齐明和德拉马尼对常见致病性非结核分枝杆菌体外抑菌活性及耐药机制的研究进展 被引量:8

In vitro activities and drug resistance mechanisms of bedaquiline,clofazimine and delamanid against common pathogenic nontuberculous mycobacteria
下载PDF
导出
摘要 近年来,非结核分枝杆菌(non-tuberculous mycobacteria,NTM)引起的感染呈逐渐上升趋势,严重威胁人类健康。NTM致病的菌种繁多,不同菌种NTM对药品的敏感性各异,使其治疗存在较大困难。因此,寻找NTM病治疗效果较佳的药品非常有必要。NTM种属分布常具有地域特点,在多数地区鸟-胞内分枝杆菌复合群、脓肿分枝杆菌和堪萨斯分枝杆菌为较常见的致病菌种。贝达喹啉(bedaquiline,Bdq)、氯法齐明(clofazimine,Cfz)及德拉马尼(delamanid,Dlm)因对治疗NTM病体现出了良好的治疗潜力而受到广泛关注。为了提高对抗NTM药品敏感性及耐药机制的认识,作者就Bdq、Cfz和Dlm对以上常见致病性NTM的体外抑菌活性及耐药相关机制进行综述。 Recently,the infection of non-tuberculous mycobacteria(NTM)has increased rapidly and threatened human health.NTM differentiate into many species.Species diversity makes treatment of NTM extremely difficult.Thus,it is very important to find new and effective drugs.Bedaquiline,clofazimine and delamanid showed effectiveness in treating NTM.In order to improve the understanding of drug susceptibility and drug resistance mechanism of NTM,in vitro activities and drug resistance mechanisms of bedaquiline,clofazimine and delamanid against common pathogenic are described.
作者 孙晴 黄海荣 王桂荣 SUN Qing;HUANG Hai-rong;WANG Gui-rong(National Clinical Laboratory on Tuberculosis,Beijing Key Laboratory for Drug Resistant Tuberculosis,Beijing Chest Hospital,Capital Medical University,Beijing Tuberculosis and Thoracic Tumor Institute,Beijing 101149,China)
出处 《中国防痨杂志》 CAS CSCD 2020年第8期880-884,共5页 Chinese Journal of Antituberculosis
基金 “十三五”国家科技重大专项(2017ZX09304009-004,2017ZX10302301-003-004) 国家自然科学基金(81703632) 北京市自然科学基金(7172050) 北京市优秀人才培养青年拔尖个人项目(2018000021223) 北京市通州区“两高”人才工程“领军人才”(YH201917)。
关键词 分枝杆菌 非典型性 贝达喹啉 氯法齐明 德拉马尼 体外研究 微生物敏感性试验 药理作用分子作用机制 综述文献(主题) Mycobacteria atypical Bedaquiline Clofazimine Delamanid In vitro Microbial sensitivity tests Molecular mechanisms of pharmacological action Review literature as topic
  • 相关文献

同被引文献50

引证文献8

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部